Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00895921 · ClinicalTrials.gov registry record · Phase 4

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

A Phase 4 study of Diabetes, sponsored by Veterans Medical Research Foundation.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT00895921 is a Phase 4 study of Diabetes that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 30 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00895921, a Phase 4 study of Diabetes, has completed, sponsored by Veterans Medical Research Foundation.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.

Conditions Studied

Interventions

  • DRUG Olanzapine
  • DRUG Aripiprazole

Study Locations (1)

California

  • VA San Diego Healthcare System - San Diego

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-11
Est. Completion 2010-06
Phase Phase 4

What the Registry Record Tells You About NCT00895921

The ClinicalTrials.gov registry entry for NCT00895921 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The listed sponsor is Veterans Medical Research Foundation, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine is the first listed.

NCT00895921 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00895921 about?

NCT00895921 is a clinical study titled "Examining the Effects of Antipsychotic Medications on Insulin Sensitivity". This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.

What is the current status of trial NCT00895921?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2008-11. Estimated completion is 2010-06.

What conditions does trial NCT00895921 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT00895921?

The interventions under investigation include: Olanzapine (DRUG), Aripiprazole (DRUG).

Who is sponsoring clinical trial NCT00895921?

This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00895921 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.